Prescriber Scope of Practice for Narcolepsy in California

If you’re a psychiatrist or PMHNP considering treating narcolepsy patients remotely, you’re probably asking: Can I legally prescribe stimulants and other controlled substances via telehealth? The short answer in 2026 is yes — but with significant caveats that vary by state and provider type.

Narcolepsy treatment relies heavily on Schedule II stimulants (Adderall, Ritalin), Schedule IV wakefulness agents (modafinil), and Schedule III medications like sodium oxybate. Under normal circumstances, federal law (the Ryan Haight Act) requires an in-person medical evaluation before prescribing any controlled substance via telemedicine. But we’re not operating under normal circumstances.

Here’s what’s actually happening right now: The DEA’s COVID-era telehealth flexibilities have been extended through December 31, 2026, allowing you to prescribe controlled substances for narcolepsy via video visit without an initial in-person exam — as long as you meet standard prescribing requirements and comply with state law. This is a temporary allowance while the DEA finalizes permanent telemedicine rules.

Let’s break down what this means for your practice, state by state, and provider type by provider type.

Federal Law: The DEA Telehealth Window Is Open (For Now)

The Ryan Haight Online Pharmacy Act normally blocks remote prescribing of controlled substances without at least one in-person visit. There are narrow exceptions (VA patients, hospital settings, covering for a colleague who saw the patient in person), but most telehealth narcolepsy care wouldn’t qualify.

COVID changed everything. In March 2020, the DEA waived the in-person requirement to prevent care disruptions. That emergency flexibility was supposed to end with the public health emergency in May 2023. Instead, recognizing the chaos that would cause, the DEA and HHS have issued four consecutive extensions. The most recent, announced January 2026, pushes the allowance through the end of 2026.

What this means practically: Right now, you can evaluate a new narcolepsy patient via secure video, confirm their diagnosis (or coordinate diagnostic sleep testing), and prescribe methylphenidate, modafinil, or other controlled medications without ever meeting them face-to-face — federally speaking.

The catch: This is explicitly temporary. The DEA is working on permanent telehealth prescribing rules. Early proposals (2023) suggested harsh limits — requiring in-person visits after 30 days, or banning remote initiation of Schedule II stimulants entirely. Pushback was fierce: over 38,000 public comments flooded in from providers, patients, and advocacy groups. The DEA has since delayed finalizing those rules, but expect some form of tightening eventually — likely requiring in-person exams for new Schedule II prescriptions, or capping initial telehealth prescriptions to 30 days.

Provider strategy: Treat the current window as a planning period. If you’re building a telehealth narcolepsy practice, design it to accommodate eventual in-person requirements — hybrid models with local clinic partnerships for physical exams and sleep studies, or concierge services that can dispatch a provider to the patient’s home if needed.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-Specific Rules: Where the Real Complexity Lives

Federal law sets the floor, but states can (and do) impose stricter requirements. If you’re licensed in multiple states or working on a multi-state platform like Klarity, you need to know these variations cold.

Florida: The Telehealth Prescribing Exception That Doesn’t Cover Narcolepsy

Florida is the outlier that will trip you up. Florida Statute 456.47 explicitly prohibits prescribing Schedule II controlled substances via telehealth — except for psychiatric disorders, inpatient care, hospice, or nursing home patients.

Here’s the problem: Narcolepsy is not a psychiatric disorder. It’s a neurological sleep disorder. So even though the DEA currently allows remote prescribing, Florida state law does not for narcolepsy stimulants.

What this means for Florida providers:

• You can prescribe modafinil or armodafinil (Schedule IV) via telehealth for narcolepsy — those aren’t banned.
• You cannot legally start Adderall, Ritalin, or other Schedule II stimulants remotely for narcolepsy.
• Workaround: Require at least one in-person visit to initiate Schedule II meds, then manage follow-ups via telehealth. Or partner with a brick-and-mortar clinic where patients can be seen physically.

For PMHNPs in Florida: You face an additional hurdle. Florida limits APRNs to 7-day supplies of Schedule II medications unless you’re a certified psychiatric nurse treating a mental health disorder. Since narcolepsy isn’t mental illness, that 7-day cap applies even if you get the patient in-person. Practically, you’ll need physician collaboration for ongoing stimulant management.

New York: State Law Now Mirrors Federal Flexibility

New York formalized its telehealth controlled substance rules in May 2025. The state does require an in-person exam before prescribing controlled substances via telehealth — unless you meet specific exceptions.

The key exception: prescribing is allowed if done ‘in accordance with applicable federal law.’ Since federal law currently permits it (DEA waiver), New York providers can prescribe narcolepsy meds via telehealth today.

When the DEA waiver expires: New York’s rule will automatically tighten. At that point, you’ll need to either:

• Conduct an in-person evaluation yourself, or
• Have the patient examined in-person by a consulting provider who refers them to you, or
• Use another Ryan Haight exception (covering for a provider who saw them, VA/IHS system, etc.)

For PMHNPs in New York: You’re in one of the best positions nationally. Experienced NPs (3,600+ hours) have full practice authority in NY — no physician oversight required. You can diagnose narcolepsy independently, order sleep studies, and prescribe all necessary controlled substances. You’ll need your own DEA registration and must check the I-STOP prescription monitoring database before each controlled prescription, but there are no NP-specific formulary restrictions.

Texas: NPs Can’t Prescribe Schedule II Stimulants (Period)

Texas is a restricted practice state with a hard rule: APRNs and PAs cannot prescribe Schedule II controlled substances in outpatient settings. The only exceptions are facility-based — hospital admissions (24+ hours), emergency departments, or hospice care.

For PMHNPs in Texas: You can prescribe modafinil (Schedule IV) under physician delegation. But for Adderall or Ritalin? You need an MD or DO to write that prescription. This creates a structural barrier to NP-led narcolepsy care in Texas.

For psychiatrists in Texas: You can prescribe stimulants via telehealth (under current DEA allowance), but Texas requires two-way audio-visual communication — a phone call alone won’t cut it for controlled substance prescriptions. Texas also prohibits telehealth prescribing for chronic pain management, but that doesn’t affect narcolepsy (it’s not a pain condition).

California: Independent NP Practice Is Here (If You’ve Logged the Hours)

California’s AB 890 created a pathway to full practice authority for NPs starting in 2023. If you’ve completed 4,600+ hours of supervised practice and met education requirements, you can practice independently — including prescribing Schedule II–V controlled substances.

For newer PMHNPs in California: You’ll still work under standardized procedures with a supervising physician until you hit those hours. But once you qualify for independent ‘104 NP’ status, you have the same prescriptive authority as a physician for narcolepsy care.

California requirements:

• Complete specified pharmacology coursework on controlled substances before furnishing Schedule II
• Obtain a DEA registration
• Check the CURES prescription monitoring database before each controlled prescription (and at least every 4 months for ongoing therapy)

No state-imposed telehealth restrictions beyond federal law. California explicitly allows telehealth exams to establish the patient relationship.

Pennsylvania: Collaboration Required, But Schedule II Limits Have Eased

Pennsylvania CRNPs (NPs) must have a collaborative agreement with a physician. You can prescribe Schedule II–V under that agreement, but with limits:

• 30-day maximum supply for Schedule II (physician must be consulted for continuation)
• 90-day limit for Schedule III–IV

Pennsylvania removed the old 72-hour restriction on Schedule II prescriptions in 2021, which was progress. But you’re still not independent.

Telehealth: Pennsylvania doesn’t prohibit controlled substance prescribing via telemedicine. The state allows establishing the patient relationship remotely and has shown flexibility (e.g., allowing telehealth buprenorphine initiation for opioid use disorder with 14-day in-person follow-up).

Practical reality: A PA PMHNP treating narcolepsy will involve the collaborating physician for periodic reviews, especially if the patient needs ongoing high-dose stimulants. The 30-day Schedule II cap means you can’t write a 90-day prescription on your own.

Illinois: Full Practice Authority With a Clean Path

Illinois allows NPs to achieve full practice authority after 4,000 clinical hours under collaboration plus 250 hours of continuing education. Once granted FPA, you can prescribe Schedule II–V independently.

One caveat: Illinois law requires NPs with FPA to maintain a ‘consultation relationship’ with a physician when prescribing benzodiazepines or opioids. Stimulants aren’t opioids, so this likely doesn’t apply to narcolepsy medications — but confirm with your malpractice carrier to be safe.

Illinois requirements:

• Mid-Level Practitioner Controlled Substance License from the state (in addition to DEA registration)
• Check the Illinois Prescription Monitoring Program before each controlled prescription
• Use electronic prescribing (paper scripts for controlled substances banned since 2023)

Illinois has strong telehealth parity and no additional state barriers to remote controlled substance prescribing beyond federal law.

Psychiatrist vs PMHNP: Who Can Do What?

Psychiatrists (MD/DO) have the cleanest path:

• Full prescriptive authority in all states (assuming you have state medical license + DEA registration)
• No formulary restrictions or supply limits unique to your provider type
• Can treat narcolepsy in any state where you’re licensed, subject only to state telehealth rules

PMHNPs face state-dependent barriers:

• Full authority states (CA, NY, IL with experience): You can diagnose and manage narcolepsy independently, including prescribing all controlled medications
• Restricted states (TX, FL in practice): You’ll need physician collaboration, and in Texas you legally cannot prescribe Schedule II at all in outpatient settings
• Reduced practice states (PA, FL): You can prescribe but with supply limits and mandatory physician oversight

The narcolepsy-specific wrinkle: Some states like Florida explicitly list approved indications for Schedule II stimulants in their regulations. Narcolepsy is on the approved list (alongside ADHD, refractory depression, epilepsy), which protects you from ‘off-label prescribing’ allegations. But if you’re treating narcolepsy as a PMHNP in Florida, you still hit the 7-day Schedule II supply cap unless you’re a certified psychiatric nurse treating a psychiatric disorder — and narcolepsy doesn’t qualify.

The Economics of Telehealth Narcolepsy Care

Here’s where regulatory complexity meets practice reality. Narcolepsy is rare (affecting roughly 1 in 2,000 Americans), often misdiagnosed, and concentrated in areas with access to sleep specialists. Telehealth can expand access dramatically — but only if you can navigate the prescribing rules.

Patient acquisition cost reality: Acquiring psychiatric patients through traditional marketing (SEO, Google Ads, directory listings) costs $200-500+ per booked patient when you factor in agency fees, ad spend, staff time to qualify leads, and no-show rates. SEO takes 6-12 months of consistent investment before generating meaningful patient flow. Google Ads for mental health keywords run $15-40+ per click, and most clicks don’t convert to appointments.

Directory listings like Psychology Today charge monthly subscription fees, and you’re competing with hundreds of other providers on the same page. Zocdoc charges per booking ($35-100+) on top of monthly subscription costs.

Platform model advantage: Platforms like Klarity Health use a pay-per-appointment model. You pay a standard listing fee per new patient lead — no upfront marketing spend, no monthly subscriptions, no wasted ad budget on clicks that don’t convert. Key value propositions:

• Pre-qualified patients already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule and only pay when you see patients

For narcolepsy specifically: Patient volume will be lower than general psychiatry, but patients often need long-term care with regular follow-ups (stimulants aren’t typically one-and-done prescriptions). The recurring revenue model works if you can legally prescribe what they need in their state.

State strategy matters: If you’re licensed in Texas, you might focus on modafinil-appropriate patients or partner with a physician for stimulant prescriptions. If you’re licensed in New York or California with full practice authority, you can handle the full patient journey independently.

What Happens When the DEA Waiver Expires?

The December 31, 2026 deadline is real. The DEA has promised permanent rules, and they’re unlikely to be as permissive as the current blanket allowance.

Most likely scenario: The DEA will require an in-person medical evaluation before initiating Schedule II stimulants via telemedicine, with possible exceptions for:

• Established patients (you’ve seen them before the rule change)
• Limited initial supplies (e.g., 30 days) followed by mandatory in-person visit
• Specific telemedicine special registration (DEA has discussed this but hasn’t implemented it)

Best-case scenario: The DEA creates condition-specific exceptions (like they did for buprenorphine in opioid use disorder) that recognize legitimate telehealth use cases for ADHD and narcolepsy stimulants.

Worst-case scenario: Strict enforcement of Ryan Haight with minimal exceptions, forcing a return to primarily in-person care for any controlled substance initiation.

How to prepare:

1. Build hybrid capability now. Establish referral relationships with local sleep centers and primary care clinics in states where you practice. If patients need in-person diagnostic testing (sleep studies almost always require in-person), you’re already coordinating local care.

2. Document thoroughly. When the rules tighten, regulators will scrutinize telehealth controlled substance prescribing. Your documentation needs to show clinical appropriateness: detailed history, mental status exam elements observable on video, rating scales (Epworth Sleepiness Scale for narcolepsy), rationale for medication choice, informed consent specific to telehealth and controlled substances.

3. Watch for DEA special registration. If the DEA creates a ‘telemedicine special registration’ system (allowing qualified clinicians to prescribe controlled substances nationwide via telemedicine), apply early. This could be the mechanism that preserves broad telehealth access.

4. Diversify your state licenses. Multi-state licensure through compacts (IMLC for physicians, APRN Compact for NPs) lets you serve patients across state lines and adapt to changing regulations. Illinois, Texas, and Pennsylvania are IMLC members for physicians. New York, Florida, and California are not (yet).

Compliance Essentials That Apply Everywhere

Regardless of state or provider type, these requirements are universal for prescribing controlled substances via telehealth:

Prescription Drug Monitoring Programs (PDMPs):

• Check your state’s PDMP before prescribing controlled substances
• Most states mandate checks for initial prescriptions and periodic reviews
• Florida (E-FORCSE), New York (I-STOP), California (CURES), Texas PMP, Pennsylvania PDMP, Illinois PMP

Electronic Prescribing:

• Federal law requires e-prescribing for Schedule II–V (with very limited exceptions)
• Your e-prescribing system must meet DEA requirements: two-factor authentication, audit trails, identity proofing
• Several states (California, Illinois, New York) have additional mandates

Standard of Care:

• Telehealth doesn’t change the standard — your exam must be as thorough as in-person
• For narcolepsy: detailed sleep history, assessment of cataplexy/sleep paralysis/hypnagogic hallucinations, screening for psychiatric comorbidities (depression, anxiety are common in narcolepsy)
• Coordinate diagnostic testing even if you can’t perform it yourself — MSLT and overnight polysomnography are typically required to confirm narcolepsy

Informed Consent:

• Document patient consent for telehealth specifically
• Explain limitations (emergency response if patient has adverse reaction to medication, technology failures, privacy considerations)
• Many states require written consent or specific telehealth disclosures

REMS Programs:

• Sodium oxybate (Xyrem, Xywav) — Schedule III medications for cataplexy — require enrollment in FDA’s Risk Evaluation and Mitigation Strategy program
• You must complete REMS training and certification to prescribe

The Bottom Line for Providers

Can you prescribe narcolepsy medications via telehealth in 2026? Yes — with state-specific limitations and an expiration date on the current federal flexibility.

Should you build a telehealth narcolepsy practice? If you’re a psychiatrist with multi-state licensure or a PMHNP in a full-practice state, absolutely. The patient need is real, the reimbursement supports it, and telehealth removes geographic barriers for a condition that’s chronically under-diagnosed.

Key considerations:

• Psychiatrists: You have maximum flexibility. Focus on states where telehealth rules are clearest (CA, NY, IL, PA, TX with the video requirement). Avoid building Florida-only practices around remote stimulant prescribing for narcolepsy.

• PMHNPs: Know your state’s scope limits cold. If you’re in Texas or Florida, you’ll need physician partnerships for Schedule II prescriptions. If you’re in New York, California, or Illinois with full practice authority, you can operate independently — but plan for eventual federal rule changes that may require in-person components.

• Platform vs solo practice: Platforms like Klarity Health remove patient acquisition risk entirely. Instead of gambling $3,000-5,000/month on marketing with uncertain ROI, you pay only when qualified patients book with you. For a specialty like narcolepsy where patient volume is inherently limited, guaranteed patient flow matters more than theoretical marketing control.

The regulatory landscape will shift. Providers who stay informed, build compliance into their workflows from day one, and maintain flexibility to adapt to rule changes will thrive. Those who assume the current DEA waiver is permanent will face disruption when it expires.

Narcolepsy patients need you. The question is whether you can navigate the legal complexity to reach them.

Frequently Asked Questions

Can I prescribe Adderall for narcolepsy via telehealth in 2026?

Yes, under current federal DEA flexibilities (extended through December 31, 2026) — except in Florida, where state law prohibits Schedule II controlled substance prescribing via telehealth for narcolepsy (it’s only allowed for psychiatric disorders, inpatient care, hospice, or nursing homes). In all other states, you can prescribe stimulants remotely if you conduct an appropriate video evaluation and meet all standard prescribing requirements.

What happens when the DEA telehealth waiver expires at the end of 2026?

The Ryan Haight Act’s in-person exam requirement will likely be enforced unless the DEA creates new exceptions in its final rules. Expect some form of in-person requirement for initiating Schedule II stimulants, possibly with limited initial supplies allowed via telehealth followed by mandatory in-person follow-up. The DEA is still finalizing permanent regulations.

Can PMHNPs prescribe narcolepsy medications in Texas?

PMHNPs in Texas can prescribe modafinil and armodafinil (Schedule IV) under physician delegation, but cannot prescribe Schedule II stimulants like Adderall or Ritalin in outpatient settings. Texas law prohibits APRNs from prescribing Schedule II except in hospitals (24+ hour admissions), emergency departments, or hospice facilities. You’ll need a collaborating physician to write those prescriptions.

Do I need to see narcolepsy patients in-person for diagnostic sleep studies?

Most narcolepsy diagnoses require objective testing — overnight polysomnography and Multiple Sleep Latency Test (MSLT) — which must be performed in-person at a sleep lab. You can coordinate these referrals remotely, but the actual diagnostic testing typically can’t be done via telehealth. Some newer home sleep studies are available for certain conditions, but narcolepsy diagnosis usually requires monitored in-lab testing.

Which states give PMHNPs the most autonomy for narcolepsy treatment?

New York, California (for experienced NPs with 4,600+ hours), and Illinois (after achieving full practice authority) allow PMHNPs to diagnose and treat narcolepsy independently, including prescribing all necessary controlled medications. These states have no NP-specific formulary restrictions on stimulants or other narcolepsy drugs.

What are the PDMP requirements for prescribing narcolepsy medications?

All states require checking the prescription drug monitoring program before prescribing controlled substances. Specific requirements vary:

• California (CURES): Check before first prescription and at least every 4 months
• New York (I-STOP): Check before each controlled substance prescription
• Florida (E-FORCSE): Mandatory check before each controlled prescription
• Texas, Pennsylvania, Illinois: Similar mandatory checks before prescribing

Can I use audio-only (phone) visits to prescribe narcolepsy medications?

Not in most states. Texas explicitly requires two-way audio-visual (video) communication for prescribing controlled substances via telehealth. Most states expect video for establishing a new patient relationship and prescribing controlled medications. Audio-only may be acceptable for established patient follow-ups in some states, but check your state medical board guidance.

How long does it take to get licensed in multiple states for telehealth narcolepsy practice?

It varies significantly. States in the Interstate Medical Licensure Compact (IMLC) — Illinois, Texas, Pennsylvania among our focus states — process applications faster (often 30-60 days for subsequent licenses after your primary state). Non-compact states like New York, Florida, and California require traditional applications taking 60-120+ days. Budget 3-6 months to establish multi-state licensure.

Sources and References

1. U.S. Department of Health & Human Services Press Release – ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (January 2, 2026) – www.hhs.gov

2. Drug Enforcement Administration – ‘DEA and HHS Extend Telemedicine Flexibilities through 2025’ (November 15, 2024) – www.dea.gov

3. Drug Enforcement Administration – ‘DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care’ (December 31, 2025) – www.dea.gov

4. 21 U.S.C. §829(e) Ryan Haight Act – Federal controlled substance prescribing requirements via Legal Information Institute, Cornell University – www.law.cornell.edu

5. Florida Statutes §456.47 – Use of Telehealth to Provide Services (2025) – www.leg.state.fl.us

Source:

• https://www.law.cornell.edu/definitions/uscode.php?defid=21-USC-1796173870-113781527&height=800&iframe=true&termoccur=999&term_src=title%3A21%3Achapter%3A13%3Asubchapter%3AI%3Apart%3AC%3Asection%3A831&width=840#:~:text=,that%20a%20prescription%20has%20been
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=promulgate%20a%20final%20set%20of,Medications%2C%E2%80%9D%20was%20submitted%20to%20the
• https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care#:~:text=On%20January%2017%2C%202025%2C%20DEA,to%20as%20the%20%E2%80%9CTwo%20Final
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.tmb.state.tx.us/page/facility-based-prescriptive-delegation#:~:text=at%20the%20hospital%E2%80%99s%20facility,from%20a%20qualified%20hospice%20provider
• https://www.cchpca.org/resources/state-telehealth-laws-and-reimbursement-policies-report-fall-2025/#:~:text=Texas%20regulations%20emphasize%20continuity%20of,Note
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=match%20at%20L114%20The%20rule,and%20the%20US%20Department%20of
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=In%20short%2C%20the%20exception%20permits,as%20a%20condition%20of%20state
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Conversely%2C%20in%20Restricted%20Practice%20states,expand%20this%20scope%20%206